Izalontamab Brengitecan Demonstrates Efficacy in Advanced Lung Cancer Trial

SystImmune and Bristol Myers Squibb announced positive Phase 3 PANKU-Lung01 study results for izalontamab brengitecan (iza-bren). The therapy significantly improved progression-free survival in patients with EGFR-mutated non-small cell lung cancer previously treated with an EGFR tyrosine kinase inhibitor. These findings, presented at ESMO 2026 and published in The Lancet, indicate a potential new treatment option for this specific patient population.